Targets › EML4
6 programs from 5 companies in 48 trials: 26 Phase 2, 11 Phase 1, 6 Phase 3, 5 Phase 4; Oncology; next expected readout Jan 2027.
Essential for the formation and stability of microtubules (MTs). Required for the organization of the mitotic spindle and for the proper attachment of kinetochores to MTs. (UniProt, Q9HC35)
Open in Phaseline: the race on EML4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Novartis | Ceritinib (LDK378) ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor; NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) inhibitor | ALK, EML4, NPM1 | Phase 4 | ALK Positive Malignancies; ALK-positive NSCLC; Neuroblastoma; ALK Positive … | Apr 2027 |
| Pfizer | crizotinib Hepatocyte growth factor receptor inhibitor; ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor | MET, ALK, EML4, NPM1, ROS1 | Phase 4 | NSCLC | Mar 2028 |
| Pfizer | Lorlatinib (PF-06463922) ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor | ALK, EML4 | Phase 4 | Non-Small-Cell Lung Cancer; Carcinoma, Non-Small-Cell Lung; Ganglioneuroblastoma; Non Small Cell Lung Cancer … | Dec 2028 |
| IDEAYA Biosciences | Crizotinib Hepatocyte growth factor receptor inhibitor; ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor | MET, ALK, EML4, NPM1, ROS1 | Phase 3 | Uveal Melanoma; Metastatic Uveal Melanoma; ALK Gene Rearrangement; Advanced Lymphoma … | Jan 2027 |
| Roche | Alectinib ALK tyrosine kinase receptor inhibitor; Tyrosine-protein kinase receptor RET inhibitor; EML4-ALK inhibitor | ALK, RET, EML4 | Phase 3 | Non-Small Cell Lung Cancer; Carcinoma, Non-Small-Cell Lung; Solid Tumors; ALK Fusion-positive Solid or CNS Tumors … | Jan 2027 |
| CStone Pharmaceuticals | Lorlatinib ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor | ALK, EML4 | Phase 2 | Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer | May 2027 |
Advanced Lymphoma (4) Non-small Cell Lung Cancer (3) Carcinoma, Non-Small-Cell Lung (3) Non Small Cell Lung Cancer (3) Metastatic Colorectal Cancer (2) Non-Small Cell Lung Cancer (2) Haematological Malignancy (2) Non Small Cell Lung Cancer Metastatic (2) Uveal Melanoma (1) Metastatic Uveal Melanoma (1) ALK Gene Rearrangement (1) Lung Cancer Stage III (1)
small molecule (5), mixed (1)
Pfizer (2) IDEAYA Biosciences (1) Roche (1) CStone Pharmaceuticals (1) Novartis (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.